AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3748494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole nafate
Number of subjects: 360
Study 3748494 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam disodium
Number of subjects: 360
Study 3748494 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 360
Study 29753888 — intervention group
Group type: EXPERIMENTAL
Intervention: Microprocessor-controlled knee (MPK, Kenevo, Otto Bock)
Number of subjects: 35
Study 29753888 — intervention group
Group type: COMPARATOR
Intervention: Non-Microprocessor-controlled knees (NMPKs)
Number of subjects: 35
Study 27438104 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Number of subjects: 1830
Study 27438104 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent
Number of subjects: 1830
Study 24912063 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 37
Study 24912063 — intervention group
Group type: COMPARATOR
Intervention: Conventional vocational services (Control)
Number of subjects: 37
Study 22300506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 200 mcg/day
Number of subjects: 22
Study 22300506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1000 mcg/day
Number of subjects: 22
Study 22300506 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 200 mcg/day and 1000 mcg/day
Number of subjects: 22
Study 20191468 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based intervention to promote physical activity (PA)
Number of subjects: 33
Study 20191468 — intervention group
Group type: COMPARATOR
Intervention: Control waiting-list group
Number of subjects: 33
Study 17070997 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 0
Study 17070997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study 17070997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15598978 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged rituximab administration (375 mg/m2 every 8 weeks for four times)
Number of subjects: 104
Study 15598978 — intervention group
Group type: COMPARATOR
Intervention: Standard schedule (375 mg/m2 weekly x 4) followed by no further treatment
Number of subjects: 104
Study 15598978 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged rituximab administration (375 mg/m2 every 8 weeks for four times) in pretreated patients
Number of subjects: 104
Study 15598978 — intervention group
Group type: COMPARATOR
Intervention: Standard schedule (375 mg/m2 weekly x 4) in pretreated patients
Number of subjects: 104
Study 11777366 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term very low doses of prednisone
Number of subjects: 0
Study 11777366 — intervention group
Group type: COMPARATOR
Intervention: High doses of prednisone
Number of subjects: 0
Study 9504939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg every eight hours)
Number of subjects: 1200
Study 9504939 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate (1 g every six hours)
Number of subjects: 1200
Study 8541559 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetastarch (HS)
Number of subjects: 36
Study 8541559 — intervention group
Group type: COMPARATOR
Intervention: Pentastarch (PS)
Number of subjects: 36
Study 2112812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal buserelin
Number of subjects: 52
Study 2112812 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous buserelin
Number of subjects: 52
Study 391210 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 50
Study 391210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30047013 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg
Number of subjects: 72
Study 27651067 — intervention group
Group type: EXPERIMENTAL
Intervention: real iTBS
Number of subjects: 27
Study 27651067 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study 25888137 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous retrograde intrarenal surgery (RIRS)
Number of subjects: 144
Study 25888137 — intervention group
Group type: COMPARATOR
Intervention: Ureteroscopy alone
Number of subjects: 144
Study 23953605 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg/day) + imidafenacin (0.1 mg 2 times a day)
Number of subjects: 308
Study 23953605 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (0.2 mg/day) alone
Number of subjects: 308
Study 21840681 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical orientation of plate-haptic IOLs (Akreos Adapt)
Number of subjects: 30
Study 21840681 — intervention group
Group type: COMPARATOR
Intervention: Horizontal orientation of plate-haptic IOLs (Akreos Adapt)
Number of subjects: 30
Study 21840681 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-piece IOLs (Acrysof SA60AT)
Number of subjects: 30
Study 21840681 — intervention group
Group type: COMPARATOR
Intervention: 3-piece IOLs (Acrysof MA60AC)
Number of subjects: 30
Study 19174069 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral diet supplements with arginine (group I)
Number of subjects: 41
Study 19174069 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous enteral formula (group II)
Number of subjects: 41
Study 16306030 — intervention group
Group type: COMPARATOR
Intervention: Regimen A (nelfinavir, stavudine, didanosine, twice-daily)
Number of subjects: 71
Study 16306030 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (nevirapine, didanosine, lamivudine, once-daily)
Number of subjects: 71
Study 16306030 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C (saquinavir, ritonavir, didanosine, lamivudine, once-daily)
Number of subjects: 71
Study 12431858 — intervention group
Group type: EXPERIMENTAL
Intervention: tryptophan-free mixture of amino acids
Number of subjects: 17
Study 12431858 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 10609977 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit group (smoking abstinence)
Number of subjects: 56
Study 10609977 — intervention group
Group type: COMPARATOR
Intervention: Continuing-to-smoke control group
Number of subjects: 56
Study 7582277 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 360 mg triamcinolone intramuscularly
Number of subjects: 19
Study 7582277 — intervention group
Group type: COMPARATOR
Intervention: Placebo triamcinolone followed by low-dose oral methotrexate (7.5 mg followed by 15 mg weekly)
Number of subjects: 19
Study 7582277 — intervention group
Group type: COMPARATOR
Intervention: Placebo triamcinolone with placebo methotrexate
Number of subjects: 19
Study 1932648 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg bolus, followed by 2 mg/min infusion)
Number of subjects: 22
Study 1932648 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline bolus and infusion)
Number of subjects: 22
Study 7048827 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 106
Study 7048827 — intervention group
Group type: COMPARATOR
Intervention: Truncal vagotomy (TV)
Number of subjects: 106
Study 31387574 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium-based compression screws
Number of subjects: 190
Study 31387574 — intervention group
Group type: COMPARATOR
Intervention: Titanium Herbert screws
Number of subjects: 190
Study 27621144 — intervention group
Group type: EXPERIMENTAL
Intervention: New tool with colored scales and target range indicator (TRI)
Number of subjects: 140
Study 27621144 — intervention group
Group type: EXPERIMENTAL
Intervention: Colors tool
Number of subjects: 140
Study 27621144 — intervention group
Group type: EXPERIMENTAL
Intervention: Smiley icons tool
Number of subjects: 140
Study 27621144 — intervention group
Group type: EXPERIMENTAL
Intervention: TRI tool
Number of subjects: 140
Study 26348767 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanol (CF) intake (450 mg bi-daily for 1 month)
Number of subjects: 100
Study 25798493 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-doula home-visiting intervention
Number of subjects: 0
Study 23204355 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral identity group
Number of subjects: 94
Study 23204355 — intervention group
Group type: COMPARATOR
Intervention: Non-moral identity group
Number of subjects: 94
Study 19732408 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular adherence counseling
Number of subjects: 621
Study 19732408 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular counseling plus a calendar
Number of subjects: 621
Study 19732408 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular counseling and a treatment assistant
Number of subjects: 621
Study 17721407 — intervention group
Group type: EXPERIMENTAL
Intervention: Welling scale rating by six independent raters
Number of subjects: 12
Study 15707190 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-randomised trial to improve maternal health
Number of subjects: 0
Study 12608650 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (DFZ) treatment for one year
Number of subjects: 10
Study 9632382 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group, seven-session HIV risk reduction program
Number of subjects: 3706
Study 9632382 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 3706
Study 9632382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition (men from STD clinics)
Number of subjects: 3706
Study 9632382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition
Number of subjects: 3706
Study 8080380 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal preperitoneal laparoscopic hernia repair
Number of subjects: 100
Study 8080380 — intervention group
Group type: COMPARATOR
Intervention: Open tension-free repairs using a polypropylene mesh
Number of subjects: 100
Study 2792658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ethanol administration (0.15 g/kg)
Number of subjects: 15
Study 2792658 — intervention group
Group type: COMPARATOR
Intervention: Oral ethanol administration (0.15 g/kg)
Number of subjects: 15
Study 2792658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal ethanol administration (0.15 g/kg)
Number of subjects: 15
Study 2792658 — intervention group
Group type: COMPARATOR
Intervention: Gastrectomy (Billroth II subtotal)
Number of subjects: 15
Study 1017533 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate ointment
Number of subjects: 20
Study 1017533 — intervention group
Group type: COMPARATOR
Intervention: Fluocinolone acetonide ointment
Number of subjects: 20
Study 1017533 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone valerate ointment
Number of subjects: 20
Study 30277987 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 120
Study 30277987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 28632742 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid increment (standard deviation) among individuals with normoglycaemia
Number of subjects: 8367
Study 28632742 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid among normoglycaemic women
Number of subjects: 8367
Study 28632742 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid among normoglycaemic men
Number of subjects: 8367
Study 28632742 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid among prediabetic men
Number of subjects: 8367
Study 28632742 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid among prediabetic women
Number of subjects: 8367
Study 28632742 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid increment (standard deviation) among individuals with prediabetes
Number of subjects: 8367
Study 26314688 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostar XL
Number of subjects: 3138
Study 26314688 — intervention group
Group type: COMPARATOR
Intervention: Perclose ProGlide
Number of subjects: 3138
Study 23617482 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy subtraction
Number of subjects: 143
Study 23617482 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided detection (CAD) alone
Number of subjects: 143
Study 23617482 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bone suppression and CAD
Number of subjects: 143
Study 23617482 — intervention group
Group type: COMPARATOR
Intervention: Original nonenhanced conventional chest radiograph
Number of subjects: 143
Study 23617482 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy subtraction and bone suppression
Number of subjects: 143
Study 23617482 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD program
Number of subjects: 143
Study 23617482 — intervention group
Group type: EXPERIMENTAL
Intervention: All modalities
Number of subjects: 143
Study 21518596 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux (2.5 mg/d)
Number of subjects: 300
Study 21518596 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin (0.1 ml/10 kg q12 h)
Number of subjects: 300
Study 18812757 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A (high-Dk)
Number of subjects: 20
Study 18812757 — intervention group
Group type: COMPARATOR
Intervention: Etafilcon A (low-Dk)
Number of subjects: 20
Study 17137026 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg twice a day intravenously and then orally, combined with amikacin 7.5 mg/Kg twice a day for a maximum of 14 days.
Number of subjects: 47
Study 17137026 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin/tazobactam 4 g/0.5 g three times a day, combined with amikacin 7.5 mg/Kg twice a day for a maximum of 14 days.
Number of subjects: 47
Study 12924687 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) in a group format, 14 sessions, small groups of 4 to 6 participants
Number of subjects: 52
Study 12924687 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 52
Study 10680039 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin sodium (Fragmin)
Number of subjects: 0
Study 10680039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8684876 — intervention group
Group type: EXPERIMENTAL
Intervention: One injection of Oka/Merck varicella vaccine
Number of subjects: 2000
Study 8684876 — intervention group
Group type: EXPERIMENTAL
Intervention: Two injections of Oka/Merck varicella vaccine
Number of subjects: 2000
Study 1654074 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy (further six courses)
Number of subjects: 369
Study 1654074 — intervention group
Group type: COMPARATOR
Intervention: No maintenance chemotherapy
Number of subjects: 369
Study 6222858 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam (10 mg/kg)
Number of subjects: 20
Study 6222858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (10 mg/kg)
Number of subjects: 20
Study 6222858 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam and Cefazolin
Number of subjects: 20
Study 31925817 — intervention group
Group type: EXPERIMENTAL
Intervention: P218 (10 mg)
Number of subjects: 64
Study 31925817 — intervention group
Group type: EXPERIMENTAL
Intervention: P218 (30 mg)
Number of subjects: 64
Study 31925817 — intervention group
Group type: EXPERIMENTAL
Intervention: P218 (100 mg)
Number of subjects: 64
Study 31925817 — intervention group
Group type: EXPERIMENTAL
Intervention: P218 (250 mg)
Number of subjects: 64
Study 31925817 — intervention group
Group type: EXPERIMENTAL
Intervention: P218 (500 mg)
Number of subjects: 64
Study 31925817 — intervention group
Group type: EXPERIMENTAL
Intervention: P218 (750 mg)
Number of subjects: 64
Study 31925817 — intervention group
Group type: EXPERIMENTAL
Intervention: P218 (1000 mg)
Number of subjects: 64
Study 31925817 — intervention group
Group type: EXPERIMENTAL
Intervention: P218 (250 mg) with food
Number of subjects: 64
Study 31925817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 31401653 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg/d)
Number of subjects: 1021
Study 31401653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1021
Study 31401653 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment effects
Number of subjects: 1021
Study 27464960 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled allergens
Number of subjects: 340
Study 27464960 — intervention group
Group type: EXPERIMENTAL
Intervention: Food allergens
Number of subjects: 340
Study 27464960 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquitous respiratory allergens (grass, olive/ash pollen, house dust mites)
Number of subjects: 340
Study 27464960 — intervention group
Group type: EXPERIMENTAL
Intervention: Regionally occurring pollen allergens (ragweed, birch, cypress)
Number of subjects: 340
Study 27464960 — intervention group
Group type: EXPERIMENTAL
Intervention: Airborne allergens cross-reacting with food allergens
Number of subjects: 340
Study 26147820 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg intranasal midazolam as premedication
Number of subjects: 60
Study 26147820 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 60
Study 24345173 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation (increased as anticipated reward decreased)
Number of subjects: 0
Study 24345173 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected reward
Number of subjects: 0
Study 24345173 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report ratings
Number of subjects: 0
Study 23529993 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1200 mg n-3 long chain polyunsaturated fatty acids)
Number of subjects: 61
Study 23529993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 19077149 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler flowmetry (LDF) used to assess bone vascularity during implant insertion.
Number of subjects: 23
Study 17726273 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg levodopa
Number of subjects: 10
Study 17726273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15342261 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults using lexical and referential information in sentence processing
Number of subjects: 2
Study 15342261 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-year-old children using verb biases in sentence processing
Number of subjects: 2
Study 11133211 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 809
Study 11133211 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 809
Study 11133211 — intervention group
Group type: COMPARATOR
Intervention: Carotid intima-media thickness
Number of subjects: 809
Study 11133211 — intervention group
Group type: COMPARATOR
Intervention: Femoral intima-media thickness
Number of subjects: 809
Study 11133211 — intervention group
Group type: COMPARATOR
Intervention: Carotid plaques
Number of subjects: 809
Study 11133211 — intervention group
Group type: COMPARATOR
Intervention: Femoral plaques
Number of subjects: 809
Study 11367872 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (T) 3 x 150 mg
Number of subjects: 24
Study 11367872 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (R) 3 x 150 mg
Number of subjects: 24
Study 9438894 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 50 mg
Number of subjects: 21
Study 9438894 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 100 mg
Number of subjects: 21
Study 9438894 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 200 mg
Number of subjects: 21
Study 9438894 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 21
Study 8288408 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg twice daily, n = 52; 50 mg twice daily, n = 16)
Number of subjects: 146
Study 8288408 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (90 mg three times daily, n = 50; 60 mg three times daily, n = 16)
Number of subjects: 146
Study 8288408 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 146
Study 8288408 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 146
Study 3688125 — intervention group
Group type: EXPERIMENTAL
Intervention: Keeping stationery
Number of subjects: 43
Study 3688125 — intervention group
Group type: COMPARATOR
Intervention: Not keeping stationery
Number of subjects: 43
Study 30539839 — intervention group
Group type: EXPERIMENTAL
Intervention: Appleby operation
Number of subjects: 17
Study 26613820 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomifene citrate (100mg daily for 5 days), metformin (850mg), and pioglitazone (15mg for 10 days)
Number of subjects: 100
Study 26613820 — intervention group
Group type: COMPARATOR
Intervention: Letrozole (5mg daily for 5 days), metformin (850mg), and pioglitazone (15mg for 10 days)
Number of subjects: 100
Study 24695986 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 (400 nmol/min)
Number of subjects: 54
Study 24695986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 22441270 — intervention group
Group type: EXPERIMENTAL
Intervention: Auriculotherapy with needles
Number of subjects: 75
Study 22441270 — intervention group
Group type: EXPERIMENTAL
Intervention: Auriculotherapy with seeds
Number of subjects: 75
Study 22441270 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 75
Study 20083625 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker (metoprolol succinate)
Number of subjects: 1200
Study 20083625 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1200
Study 18419890 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentralised TB services at township hospitals
Number of subjects: 171
Study 18419890 — intervention group
Group type: COMPARATOR
Intervention: Control groups (township hospitals referring to county TB dispensaries)
Number of subjects: 171
Study 16162465 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive self-care health book
Number of subjects: 1967
Study 16162465 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-tree based self-care health book
Number of subjects: 1967
Study 16162465 — intervention group
Group type: COMPARATOR
Intervention: No-book control condition
Number of subjects: 1967